5 Amendments of Miroslav MIKOLÁŠIK related to 2016/2057(INI)
Amendment 98 #
Motion for a resolution
Recital E a (new)
Recital E a (new)
Ea. whereas the pharmaceutical sector takes advantage of various innovation incentives such as supplementary protection certificate, data exclusivity or market exclusivity which aim at promoting valuable innovation fulfilling unmet medical needs, and whereas these incentives do not always prove to attain those objectives.
Amendment 123 #
Motion for a resolution
Recital G
Recital G
G. whereas, due to the current international reference pricing system, the prices of medicines are usually negotiated by means of bilateral and confidential negotiations between the pharmaceutical industry and Member States;
Amendment 133 #
Motion for a resolution
Recital I
Recital I
I. whereas the entry of generics and biosimilars onto the market is an important mechanism to reduce prices, and whereas there are clear concerns about the strategies to delay this entry;
Amendment 148 #
Motion for a resolution
Recital J a (new)
Recital J a (new)
Ja. Whereas the European Parliament has shown its strong political commitment to this matter, above all by opening its current legislature to a more open policy for access to medicines;
Amendment 464 #
Motion for a resolution
Paragraph 23
Paragraph 23
23. Calls on the Commission to take a very cautious approach and guarantee safety and efficacy in any fast- track approval process and to introduce the concept of conditional authorisation based on effectiveness; in this respect, calls on the Commission to take into consideration the opinion of non-industry related stakeholders;